Clinical Study
Imatinib Mesylate Effectiveness in Chronic Myeloid Leukemia with Additional Cytogenetic Abnormalities at Diagnosis among Black Africans
Table 3
Therapeutic and evolutionary features.
| | Variables | Numbers (%) |
| | Evolutionary phase | | | Chronic phase | 18 (67) | | Accelerated phase | 9 (33) | | Hematologic remission | | | Complete | 16 (59) | | Partial | 11 (41) | | Cytogenetic or molecular remission | | | Major cytogenetic response (Ph+ ≤ 35%) | 14 (52) | | Complete cytogenetic response (Ph+ 0%) | 7 (26) | | Partial cytogenetic response (Ph+ 1%–35%) | 7 (26) | | Minor cytogenetic response (Ph+ 36%–95%) | 8 (30) | | Minimal cytogenetic response (Ph+ 96%–100%) | 4 (15) | | Complete molecular response | 1 (3) | | Outcome | | | Alive | 17 (63) | | Dead | 10 (37) | | Causes of death | | | Acutisation | 3 (30) | | Hematologic toxicity | 4 (40) | | Pulmonary tuberculosis | 1 (10) | | Epilepsy | 1 (10) | | Unspecified | 1 (10) | | Adverse effects grade 3 and 4 | | | Hematologic toxicity | | | Anemia | 10 (37) | | Leukopenia | 9 (33) | | Thrombocytopenia | 8 (29) | | Duration of follow-up (median and extreme values in months) | 37 (4–87) |
|
|
